Injecting Daromun for treating non-melanoma skin cancer

A Phase II Study of Intratumoral Administration of L19IL2/L19TNF in Non-melanoma Skin Cancer Patients With Presence of Injectable Lesions

This study is testing if injecting a new treatment directly into tumors can help people with high-risk skin cancers who can’t have surgery.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years to 100 Years
• Sex: All
• Sponsor: Philogen S.p.A. (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy, radiation
• Locations: 11 sites (Augsburg and 10 other locations)
• Trial ID: NCT04362722 on ClinicalTrials.gov

What this trial studies

This phase II clinical trial investigates the effectiveness of intratumoral injections of L19IL2 and L19TNF in patients with high-risk basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC). The study aims to provide a non-invasive treatment option for patients who cannot undergo surgery due to various reasons, such as the tumor's location or patient preference. Participants will receive a specific dosage of L19IL2 and L19TNF directly into their tumors, with the goal of achieving favorable tumor responses and improved recurrence-free survival. The trial focuses on patients with localized, non-metastatic tumors that are suitable for this type of injection.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 to 100 with high-risk, localized BCC or cSCC that can be injected.

Not a fit: Patients with metastatic disease or those who are not suitable for intratumoral injection may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a non-invasive alternative for patients with non-melanoma skin cancer, potentially improving their outcomes and quality of life.

How similar studies have performed: Previous studies have shown promising results with similar intralesional treatments in melanoma, suggesting potential for success in this approach for BCC and cSCC.

Eligibility criteria

Inclusion Criteria:

* High-risk, localized (non-metastatic, node negative, single or multifocal) BCC or cSCC amenable to intratumoral injection.
* Patients with injectable and measurable regional cutaneous or subcutaneous in-transit or satellite metastasis but without regional nodal involvement are also eligible.
* Male or female patients, age 18 - 100 years.
* ECOG Performance Status/WHO Performance Status ≤ 1.
* Hemoglobin \> 10.0 g/dL.
* Platelets \> 100 x 10\^9/L.
* ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN).
* Serum creatinine \< 1.5 x ULN and GFR \> 60 mL/min.
* All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.
* Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomised partner.
* Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.
* Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

* Previous or concurrent cancer type that is distinct from the cancers being evaluated in this study, except any cancer curatively treated more than 2 years prior to study entry.
* Patients may have previously received topical or systemic chemotherapy, immunotherapy or radiation therapy on the tumor sites. Such therapies must be completed at least 4 weeks prior to study drug administration.
* Patients with node positive BCC/cSCC who are candidate to SHH inhibitor or checkpoint inhibitor therapy.
* Presence of active severe bacterial or viral infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study. In particular a documented test for HIV, HBV and HCV excluding active infection is needed.
* History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris, inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
* Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
* Known arterial aneurysms.
* INR \> 3.
* Uncontrolled hypertension.
* Known uncontrolled coagulopathy or bleeding disorder.
* Known hepatic cirrhosis or severe pre-existing hepatic impairment.
* Moderate to severe respiratory failure.
* Active autoimmune disease.
* Patient requires or is taking systemic corticosteroids (\>5 mg/day) or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.
* Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
* Pregnancy or breast-feeding.
* Ischemic peripheral vascular disease (Grade IIb-IV).
* Severe diabetic retinopathy.
* Recovery from major trauma including surgery within 4 weeks prior to enrollment.
* Solid organ transplant recipient or patient with iatrogenic or pathologic severe immune suppression.
* Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.

Where this trial is running

Augsburg and 10 other locations

• Universitätsklinikum Augsburg — Augsburg, Germany (Recruiting)
• Charité Universitätsmedizin Berlin — Berlin, Germany (Recruiting)
• University Hospital Carl Gustav Carus — Dresden, Germany (Not_yet_recruiting)
• Universitätsklinikum Essen (AöR) — Essen, Germany (Recruiting)
• Nationales Centrum für Tumorerkrankungen (NCT) — Heidelberg, Germany (Recruiting)
• University Medical Center Schleswig Holstein — Kiel, Germany (Recruiting)
• Universitätsklinikum Regensburg — Regensburg, Germany (Recruiting)
• Tübingen University Hospital — Tübingen, Germany (Recruiting)
• Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa — Warsaw, Poland (Recruiting)
• Kantonsspital St.Gallen, Clinical Trials Unit, Dermatologie und Venerologie — Saint Gallen, Switzerland (Recruiting)
• Universitätsspital Zürich (USZ) — Zürich, Switzerland (Recruiting)

Study contacts

• Study coordinator: Giuliano Elia, PhD

Conditions Carcinoma, Basal Cell; Carcinoma, Cutaneous Squamous Cell